Telomerase is a ribonucleoprotein (RNP) complex that synthesizes telomere repeats in tissue progenitor cells and cancer cells. Active human telomerase consists of at least three principal subunits, including the telomerase reverse transcriptase (TERT), the telomerase RNA (TERC), and dyskerin. Here, we identify a holoenzyme subunit, TCAB1 (telomerase Cajal body protein1), uniquely enriched in Cajal bodies, nuclear sites of RNP processing important for telomerase function. TCAB1 associates with active telomerase enzyme, with established telomerase components, and with small Cajal body RNAs involved in modifying splicing RNAs. Depletion of TCAB1 using RNA interference prevents TERC from associating with Cajal bodies, disrupts telomerase-telomere association and abrogates telomere synthesis by telomerase. Thus, TCAB1 controls telomerase trafficking and is required for telomere synthesis in human cancer cells.TERT and TERC comprise the minimal catalytic core of the telomerase enzyme (1), whereas dyskerin is an RNA binding protein that recognizes the H/ACA sequence motif shared by TERC and two groups of non-coding RNAs involved in RNA modification -small Cajal body (sca) RNAs and small nucleolar (sno) RNAs (2,3). Dyskerin functions in part to support telomerase RNP biogenesis and TERC stability (4,5). TERT, TERC and dyskerin are all components of active telomerase (6), and mutations in any of these genes can cause the human stem cell disorder dyskeratosis congenita (7). Other potential components of active telomerase include three evolutionarily conserved dyskerin-associated proteins, NOP10, NHP2 and GAR1 (8-10), and EST1A, a homologue of the yeast telomerase protein Est1p (11,12). However, the size of active human telomerase, estimated in the 0.65 to 2 MDa range (6,13,14), suggests the existence of additional components. We reasoned that other dyskerin-associated proteins may be telomerase components, and we therefore sought to purify dyskerin complexes.To study dyskerin, we expressed tagged dyskerin protein at endogenous levels in the absence of competing endogenous protein (Fig. S1) and isolated dyskerin complexes using a dual affinity chromatography strategy. Purified dyskerin complexes were analyzed by SDS-PAGE and nanoLC-MS/MS for identification of co-purifying proteins (Fig. 1A,B). Dense peptide coverage was obtained for dyskerin and for the dyskerin-associated ATPases pontin and reptin (14). Each of the evolutionarily conserved dyskerin-binding proteins NHP2, NOP10 and GAR1 was detected, as were the dyskerin-associated proteins Nopp140 and NAF1, a nucleoplasmic factor required for assembly of H/ACA RNPs including telomerase (15) (Fig. 1B). In addition, this approach identified the WD40 repeat protein WDR79, a protein that had not been previously implicated in dyskerin or telomerase function.We further characterized WDR79, hereafter referred to as TCAB1 (Fig. 1B, S2). Endogenous TCAB1 was specifically bound to Flag-dyskerin immunoprecipitated from Flagdyskerin +shRNA HeLa cells, as were endogenous ponti...
Recruitment to telomeres is a pivotal step in the function and regulation of human telomerase; however, the molecular basis for recruitment is not known. Here, we have directly investigated the process of telomerase recruitment via fluorescence in situ hybridization (FISH) and chromatin immunoprecipitation (ChIP). We find that depletion of two components of the shelterin complex that is found at telomeres-TPP1 and the protein that tethers TPP1 to the complex, TIN2-results in a loss of telomerase recruitment. On the other hand, we find that the majority of the observed telomerase association with telomeres does not require POT1, the shelterin protein that links TPP1 to the single-stranded region of the telomere. Deletion of the oligonucleotide/oligosaccharide binding fold (OB-fold) of TPP1 disrupts telomerase recruitment. In addition, while loss of TPP1 results in the appearance of DNA damage factors at telomeres, the DNA damage response per se does not account for the telomerase recruitment defect observed in the absence of TPP1. Our findings indicate that TIN2-anchored TPP1 plays a major role in the recruitment of telomerase to telomeres in human cells and that recruitment does not depend on POT1 or interaction of the shelterin complex with the single-stranded region of the telomere.
SUMMARY Specific information about how telomerase acts in vivo is necessary for understanding telomere dynamics in human tumor cells. Our results imply that under homeostatic telomere length-maintenance conditions only one molecule of telomerase acts at each telomere during every cell division and processively adds ~60 nt to each end. In contrast, multiple molecules of telomerase act at each telomere when telomeres are elongating (non-equilibrium conditions). Telomerase extension is less processive during the first few weeks following the reversal of long-term treatment with the telomerase inhibitor GRN163L, a time when Cajal bodies fail to deliver telomerase RNA to telomeres. This result implies that processing of telomerase by Cajal bodies may affect its processivity. Overexpressed telomerase is also less processive than the endogenously expressed telomerase. These findings reveal two major distinct extension modes adopted by telomerase in vivo.
Telomere maintenance by telomerase is critical for the unlimited division potential of most human cancer cells. The two essential components of human telomerase, telomerase RNA (hTR) and telomerase reverse transcriptase (hTERT), are recruited from distinct subnuclear sites to telomeres during S phase. Throughout the remainder of the cell cycle hTR is found primarily in Cajal bodies. The localization of hTR to Cajal bodies and telomeres is specific to cancer cells where telomerase is active and is not observed in primary cells. Here we show that the trafficking of hTR to both telomeres and Cajal bodies depends on hTERT. RNA interference-mediated depletion of hTERT in cancer cells leads to loss of hTR from both Cajal bodies and telomeres without affecting hTR levels. In addition, expression of hTERT in telomerase-negative cells (including primary and ALT cancer cell lines) induces hTR to localize to both sites. Factors that did not stimulate hTR localization in our experiments include increased hTR RNA levels and Cajal body numbers, and expression of SV40 large T antigen and oncogenic Ras. Our findings suggest that the trafficking of telomerase to Cajal bodies and telomeres in cancer cells correlates with and depends on the assembly of the enzyme.
Human telomerase is a ribonucleoprotein (RNP) that synthesizes DNA repeats at the ends of chromosomes and maintains telomere length and genome stability. The enzyme comprises telomerase RNA (hTR) (which provides the template for telomere addition) and several protein subunits, including telomerase reverse transcriptase (hTERT) (the catalytic component). Intracellular trafficking of the enzyme has emerged as an important factor in the regulation of telomerase activity. Telomerase trafficking between nuclear Cajal bodies (proposed sites of telomerase biogenesis and regulation) and telomeres (sites of action) is regulated by the cell cycle in concordance with telomere synthesis during S phase. Here, we describe fluorescence microscopy approaches to visualize the subcellular localization of the essential RNA component of hTR relative to Cajal bodies and telomeres in cultured human cells. These methods include fluorescence in situ hybridization (to detect hTR and telomeric DNA) and immunofluorescence (IF) (to detect Cajal bodies and telomere-binding proteins). Because telomerase localization to telomeres is normally restricted to S phase, we also describe methods to synchronize and analyze cells within this phase of the cell cycle.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.